Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
05 January 2024 - 3:45AM
Saint-Herblain (France), January 4,
2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a
specialty vaccine company, today announces that members of its
management team including Thomas Lingelbach, CEO and Peter
Bühler, CFO will hold investor meetings during the 42nd Annual
J.P. Morgan Healthcare Conference, January 8 – 10, 2024 in San
Francisco and virtually at the Oddo BHF Forum on January
15,2024.
Valneva’s CEO and CFO will notably discuss the
Company’s advanced vaccine development pipeline, including its Lyme
disease vaccine candidate VLA15 (Phase 3 fully enrolled, partnered
with Pfizer), as well as the Company’s growing commercial business,
which now includes recently FDA-approved1 IXCHIQ®, the world’s
first licensed vaccine for prevention of disease caused by
chikungunya virus, launching in early 2024.
To schedule a 1on1 investor meeting with
Valneva, institutional investors and analysts cancontact Valneva’s
investor relations department at investors@valneva.com.
About Valneva SEWe are a
specialty vaccine company that develops, manufactures, and
commercializes prophylactic vaccines for infectious diseases
addressing unmet medical needs. We take a highly specialized and
targeted approach, applying our deep expertise across multiple
vaccine modalities, focused on providing either first-, best- or
only-in-class vaccine solutions.
We have a strong track record, having advanced
multiple vaccines from early R&D to approvals, and currently
market two proprietary travel vaccines as well as certain
third-party vaccines leveraging our established commercial
infrastructure.
Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the world’s first vaccine against the chikungunya virus
and the only Lyme disease vaccine candidate in advanced clinical
development, which is partnered with Pfizer, as well as vaccine
candidates against the Zika virus and other global public health
threats.
About
IXCHIQ®In the U.S.,
IXCHIQ® is a live-attenuated vaccine indicated for
the prevention of disease caused by chikungunya virus (CHIKV) in
individuals 18 years of age and older who are at increased risk of
exposure to CHIKV. As for all products approved under FDA’s
accelerated approval pathway, continued approval for this
indication is contingent upon verification and description of
clinical benefit in confirmatory studies.
Please click here for
full Prescribing Information for
IXCHIQ®.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineVP
Global Communications & European Investor RelationsM +33 (0)6
4516 7099laetitia.bachelot-fontaine@valneva.com
|
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing, results and
completion of research, development and clinical trials for product
candidates, to regulatory approval of product candidates and review
of existing products. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or
developments of Valneva may not be sustained in the future. In some
cases, you can identify forward-looking statements by words such as
“could,” “should,” “may,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
and delays involved in the development and manufacture of vaccines,
unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, and the ability to obtain
or maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
1 Valneva Announces U.S. FDA Approval of World’s First
Chikungunya Vaccine, IXCHIQ® - Valneva
- 2024_01_04_VLA_JPM_Oddo_PR_EN
Valneva (EU:VLA)
Historical Stock Chart
From Apr 2024 to May 2024
Valneva (EU:VLA)
Historical Stock Chart
From May 2023 to May 2024